SOURCE: StockCall


September 21, 2010 09:33 ET

Analyst Research on Mylan and Watson Pharmaceuticals - Generic Drugs Makers Look Set For Breakthrough

JOHANNESBURG, SOUTH AFRICA--(Marketwire - September 21, 2010) - offers investors comprehensive research on the drugs - generic industry and has completed analytical research on Mylan Inc. (NASDAQ: MYL) and Watson Pharmaceuticals Inc. (NYSE: WPI). Register with us today at to have free access to these researches. 

The Generic Drug sector has been strong lately as demand for generic drugs is increasing. Now up to around 70% of the total prescription volume, generic drug use should continue to increase as many top selling patents are slated to expire through 2014 largely benefitting players like Watson Pharmaceuticals Inc. One potential obstacle to growth is the European Union's decision to cut prices on its generic offerings. Investors looking for complimentary research on Watson Pharmaceuticals Inc. are welcome to sign up at for our new report. is an online platform where investors doing their due-diligence on the drugs - generic industry can have easy and free access to our analyst research and opinions on Mylan Inc. and Watson Pharmaceuticals Inc.; all investors need to do is register for a complimentary membership at

As the demand for generic increases, it is expected that the sector should continue its trend of consolidation. On the M&A level, Mylan Inc. one of the behemoth in this industry has recently completed its acquisition of Ireland-based Bioniche Pharma Holdings Ltd. Without any form of patent protection, the generic drug market is very similar to commodities where cost is the primary driving factor among purchasers. Companies hope that by consolidating in the historically fractured sector that they will be able to achieve economies of scale that allow them to decrease their prices. Investors looking for free research on Mylan Inc. are welcome to sign up at for our new report. 

One recent development within the industry was a governmental ruling that upheld the legality of generic drug patent settlements. While the Federal Trade Commission maintains that "pay-for-delay" settlements are anti-competitive, the practice of brand name companies paying others not to produce generic versions of their product remains legal. This should be good news for the sector as long as the FTC remains inactive. Register now at to have free access to our reports on the drugs - generic industry.

Visit to see how companies in this industry have grown over the past years and how they are expected to perform in the future.

About is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines.

Contact Information